Tirzepatide Subcutaneous Injection
  1. Home
  2. Mounjaro
  3. Tirzepatide Subcutaneous Injection

Tirzepatide Subcutaneous Injection

Tirzepatide Subcutaneous Injection is a prescription dual GIP and GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and, for certain formulations, to support chronic weight management. It is administered as a once-weekly subcutaneous injection using a sterile prefilled injection pen. The long-acting formulation provides convenient and consistent metabolic management with scheduled dosing.

BUY NOW

Category

Tirzepatide Subcutaneous Injection contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose and body weight by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. The once-weekly injectable formulation delivers sustained therapeutic activity and is widely prescribed for the management of type 2 diabetes and selected chronic weight management programs. Manufactured under stringent pharmaceutical quality standards, the sterile prefilled injection pen is engineered for precise subcutaneous administration and dependable clinical performance across multiple dosage strengths. Tirzepatide Subcutaneous Injection should be used only under the supervision of a qualified healthcare professional according to the prescribed treatment plan.

Technical Specification

Specification Details
Product Name Tirzepatide Subcutaneous Injection
Active Ingredient Tirzepatide
Dosage Form Prefilled Injection Pen
Route of Administration Subcutaneous Injection
Dosing Frequency Once Weekly (As Prescribed)
Storage Refrigerate at 2°C–8°C before first use

Product Also Known As

Tirzepatide Subcutaneous Injection, Tirzepatide Injection, Weekly Tirzepatide Injection, Tirzepatide Prefilled Pen, GIP GLP-1 Receptor Agonist Injection, Diabetes Injection Pen, Weight Management Injection